| 569 |
October/2020 |
Natalizumab |
Natalizumab for the treatment of relapsing-remitting multiple sclerosis after the first treatment failure |
| 564 |
October/2020 |
Naproxen |
Expansion of the use of naproxen for the treatment of reactive arthritis |
| 561 |
2020/September |
Ocrelizumab |
Ocrelizumab for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) as an alternative or when there is a contraindication to natalizumab |
| 560 |
2020/September |
Dabigatran etexilate and idarucizumab |
Dabigatran for prevention of stroke in patients over 60 years with non-valvular atrial fibrillation who are unable to remain in the therapeutic range of international normalized ratio with warfarin and idarucizumab for reversing the anticoagulant effect of dabigatran |
| 559 |
2020/September |
Bortezomib |
Bortezomib for the treatment of adult patients with previously untreated multiple myeloma who are ineligible for autologous haematopoietic stem cell transplantation |
| 558 |
2020/September |
Bortezomib |
Bortezomib for the treatment of adult patients with previously untreated multiple myeloma who are eligible for autologous haematopoietic stem cell transplantation |
| 557 |
2020/September |
Bortezomib |
Bortezomib for the treatment of adult patients with previously treated multiple myeloma |
| 556 |
2020/September |
Meningococcal ACWY |
Meningococcal ACWY (conjugate) vaccine for adolescents aged 11–12 years in the National Vaccination Schedule |
| 552 |
2020/August |
Risedronate 5mg tablets |
Exclusion of risedronate 5mg for the treatment of patients with Paget’s disease |
| 549 |
2020/August |
Ranibizumab |
Ranibizumab for the treatment of diabetic macular edema (DME) |
| 548 |
2020/August |
Automated liquid culture for detection of mycobacteria and susceptibility testing to antimicrobials used in the treatment of tuberculosis |
Automated liquid culture for detection of mycobacteria and susceptibility testing to antimicrobials used in the treatment of tuberculosis |
| 547 |
2020/August |
Delamanid (Deltyba®) |
Delamanid for the treatment of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis |
| 546 |
2020/August |
Bedaquiline (Sirturo®) |
Bedaquiline for patients with rifampicin-resistant, multidrug-resistant and extensively drug-resistant tuberculosis |
| 545 |
2020/August |
Universal testing for hepatitis C in pregnant women in the first trimester of pregnancy during antenatal care |
Universal testing for hepatitis C in pregnant women in antenatal care |
| 544 |
2020/August |
Levothyroxine sodium |
Inclusion of levothyroxine sodium presentations of 12.5 and 37.5 mcg for treatment of congenital hypothyroidism |
| 541 |
2020/June |
Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) |
Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) for the first-line treatment of advanced (unresectable and metastatic) melanoma |
| 540 |
2020/July |
Vestronidase alfa (Mepsevii®) |
Vestronidase alfa for the treatment of mucopolysaccharidosis type VII |
| 539 |
2020/June |
Sirolimus |
Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis |
| 538 |
2020/June |
Tofacitinib Citrate (Xeljanz®) |
Tofacitinib citrate for the treatment of moderate to severe ulcerative colitis in adult patients with inadequate response, loss of response or intolerance to previous treatment with conventional synthetic or biological drugs |
| 537 |
2020/July |
Tofacitinib Citrate (Xeljanz®) |
Tofacitinib citrate for the treatment of moderate to severe active psoriatic arthritis in adult patients with intolerance or treatment failure with synthetic or biological disease-modifying antirheumatic drugs (DMARDs) |
| 536 |
2020/August |
Ixekizumab (Taltz®) |
Ixekizumab for the treatment of active psoriatic arthritis in adult patients with an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs) |
| 535 |
2020/August |
Ixekizumab |
Ixekizumab for the treatment of adult patients with moderate to severe psoriasis with treatment failure, contraindication or intolerance to adalimumab |
| 534 |
2020/September |
Risankizumab (SKYRIZI®) |
Risankizumab for the treatment of adult patients with moderate to severe plaque psoriasis |
| 533 |
2020/June |
Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) |
Increasing the upper age limit to 75 years for allogeneic Haematopoietic Stem Cell Transplantation (HSCT) procedures |
| 532 |
2020/June |
Human anti-hepatitis B immunoglobulin |
Human anti-hepatitis B immunoglobulin 1,000 IU |
| 531 |
2020/June |
Ruxolitinib (Jakavi®) |
Ruxolitinib for the treatment of patients with primary myelofibrosis, postpolycythaemia vera myelofibrosis or postessential thrombocythaemia myelofibrosis, in people with intermediate-2 or high-risk disease |
| 526 |
2020/June |
Rifapentine plus isoniazid (3HP regimen) |
Rifapentine plus isoniazid for treatment of Latent Mycobacterium Tuberculosis Infection (LTBI) |
| 525 |
2020/June |
Rifampicin 300 mg capsule, and 20 mg/mL oral suspension |
Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease |
| 524 |
2020/March |
Empagliflozin and Dapagliflozin |
Empagliflozin and Dapagliflozin for the treatment of Type 2 Diabetes Mellitus |
| 523 |
2020/March |
Orlistat |
Orlistat for weight loss in overweight or obese patients |
| 522 |
2020/March |
Sibutramine |
Sibutramine for the treatment of obese patients |
| 519 |
2020/March |
Riociguat |
Riociguat for inoperable or persistent/recurrent after surgical treatment Chronic Thromboembolic Pulmonary Hypertension |
| 518 |
2020/April |
Treatment of Pseudomyxoma Peritonei |
Cytoreductive surgery (peritonectomy) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) |
| 517 |
2020/April |
Cytoreductive surgery (peritonectomy) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) |
Cytoreductive surgery with hyperthermic chemotherapy in patients with malignant peritoneal mesothelioma |
| 516 |
2020/March |
Newborn Screening |
Newborn Screening for Congenital Toxoplasmosis |
| 515 |
2020/March |
Dolutegravir |
Dolutegravir for the treatment of pregnant women living with HIV |
| 510 |
2020/March |
Baricitinib (Olumiant®) |
Baricitinib (Olumiant®) for patients with moderate to severe Active Rheumatoid Arthritis |
| 509 |
2020/March |
Mirabegron |
Mirabegron for the treatment of storage dysfunction in patients with Neurogenic Bladder |
| 508 |
2020/March |
Oxybutynin, Tolterodine, Solifenacin and Darifenacin |
Antimuscarinics (Oxybutynin, Tolterodine, Solifenacin and Darifenacin) for the treatment of Storage Dysfunction in patients with Neurogenic Bladder |
| 507 |
2020/March |
Photodynamic Therapy |
Photodynamic Therapy for non-melanoma skin cancer |
| 506 |
2020/February |
Personal Frequency Modulation System |
Personal frequency modulation system for hearing-impaired students at any age and at any academic level |
| 503 |
2020/January |
Testing for prothrombin gene mutation (G202110A), protein C functional assay, protein S functional assay, anti-beta2-glycoprotein I - IgG, lupus anticoagulant |
Diagnostic tests for thrombophilia in pregnancy |
| 501 |
2019/November |
Pyrazinamide 150 mg dispersible tablets |
Incorporation of pyrazinamide 150 mg dispersible tablets in the Brazilian National Relation of Essential Medicines (RENAME in Portuguese) |